Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Advertising, Marketing & Sales Regulation Australia

Tougher Sanctions And Penalties Kick In For Advertising Breaches In Australia

  • News

Executive Summary

Australia has introduced new civil penalties and amended criminal offence provisions for breaches of its therapeutic product advertising rules. More reforms to the advertising regulations are expected soon.

You may also be interested in...



Australia Moves To Further Improve Advertising Framework

A review of therapeutic goods advertising reforms that were introduced in Australia in 2018 calls for further changes to support implementation and compliance.

Pharma Given Just Days To Say Whether Australian Bills Make Sense

Australian regulators are planning to introduce in Parliament in September two bills related to legislative amendments being made in response to last year’s Medicines and Medical Devices Regulation expert panel review.

Migraine & Hepatitis B Prevention Products Among New EU Filings

The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.

Table

View full table

Topics

Tags:
Advertising, Marketing & Sales Regulation Australia
UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By